Ovarian cancer patients had a twofold greater risk of gastrointestinal adverse effects when bevacizumab was added to chemotherapy, but the angiogenesis inhibitor did not exacerbate other known risks for GI events, data from a large prospective trial showed.
Ovarian cancer patients had a twofold greater risk of gastrointestinal adverse effects when bevacizumab was added to chemotherapy, but the angiogenesis inhibitor did not exacerbate other known risks for GI events, data from a large prospective trial showed.
Most survivors of gynecologic cancers have menopausal symptoms, and at least one in four takes replacement hormones, results of the first study of its kind showed.
Developers of a genetic-susceptibility test for ovarian cancer might have jumped the gun, according to an OCRF-funded research consortium that found no association between a KRAS mutation and risk of the cancer.
Cancer recurrence and death occurred significantly more often in ovarian cancer patients treated with erythropoietin-stimulating agents (ESAs), data from a retrospective cohort review showed.
Almost half of patients with heavily pretreated ovarian cancer benefited from an investigational PARP inhibitor, results of a phase I study showed.
Changes in expression of a microRNA showed potential for predicting response to the angiogenesis inhibitor bevacizumab (Avastin) in recurrent serous ovarian cancer, according to results of a small study reported here.
Most older patients with ovarian cancer may receive care that doesn't measure up to national standards, according to an analysis of a National Cancer Institute (NCI) database and Medicare claims data.
12/21/2010 Available ovarian cancer screening only slightly reduces the number of deaths from the disease, a new study finds. Until more sensitive screening tests can be developed, other strategies, such as better prevention and treatment, are needed to significantly reduce deaths from ovarian cancer, the researchers from Duke University Medical Center said. OCRF sponsored researcher, … Continued
11/08/2010 OCRF Grantee Lin Zhang, MD Research has provided strong support for the ovarian cancer stem cell hypothesis, which proposes that a rare subpopulation of tumor cells—cancer stem cells– have the unique ability to initiate and perpetuate tumor growth. The studies in Dr. Lin Zhang’s laboratory, which were supported by an OCRF Liz Tilberis award, have provided … Continued
09/28/2010 View a seven-part series about ovarian cancer, brought to you by the Ovarian Cancer Research Fund.The series is narrated by Douglas A. Levine, MD, of Memorial Sloan-Kettering Cancer Center. Dr. Levine is a member of OCRF’s Scientific Advisory Committee.The video also features OCRF Board Members Carmel Cohen, MD and Robin Zarel.
Some of you may have recently seen articles in the newspaper or on TV about a test called OVA1. OVA1 is a test approved by the FDA which measures the levels of five proteins in blood samples from women with a known ovarian mass that have been reported to change when ovarian cancer is present. … Continued
Get email updates about research news, action alerts, and ways to join the fight.
